Fulcrum Therapeutics (FULC) Cash from Operations (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Cash from Operations of 16039000.0 for Q2 2026, down 16.06% year-over-year from 19106885.61 in Q2 2025, and up 14.46% quarter-over-quarter from 18750000.0 in Q1 2026.
Powered by 
Analysis
Fulcrum Therapeutics (FULC) Cash from Operations (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Cash from Operations for 9 consecutive years, with 16039000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Operations fell 16.06% year-over-year to 16039000.0; the TTM figure through Jun 2026 stood at 65777000.0 (down 1.34% YoY), while the FY2025 annual figure was 60065000.0, down 2608.07% from the prior year.
- Cash from Operations advanced to 16039000.0 in Q2 2026 per FULC's latest filing, from 18750000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 58899000.0 in Q2 2024 and bottomed at 27882000.0 in Q3 2022.
- Historically, Cash from Operations has averaged 15838166.67 across 5 years, with a median of 19384000.0 in 2022.
- Annual changes were most pronounced in 2024 — Cash from Operations surged 383.37% — and 2025, when it tumbled 123.46%.
- Fulcrum Therapeutics' Cash from Operations stood at 19696000.0 in 2022, then decreased by 17.58% to 23158000.0 in 2023, then grew by 27.62% to 16761000.0 in 2024, then declined by 0.22% to 16798000.0 in 2025, then climbed by 4.52% to 16039000.0 in 2026.
- Business Quant data shows FULC's Cash from Operations at 16039000.0 in Q2 2026, 18750000.0 in Q1 2026, and 16798000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Fulcrum Therapeutics | 293.24 Mn | 293.24 Mn | - | -16.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16.04 Mn |
| Mar 31, 2026 | -18.75 Mn |
| Dec 31, 2025 | -16.80 Mn |
| Sep 30, 2025 | -14.19 Mn |
| Jun 30, 2025 | -13.82 Mn |
| Mar 31, 2025 | -15.26 Mn |
| Dec 31, 2024 | -16.76 Mn |
| Sep 30, 2024 | -19.07 Mn |
| Jun 30, 2024 | 58.90 Mn |
| Mar 31, 2024 | -25.28 Mn |
| Dec 31, 2023 | -23.16 Mn |
| Sep 30, 2023 | -22.91 Mn |
| Jun 30, 2023 | -20.79 Mn |
| Mar 31, 2023 | -24.12 Mn |
| Dec 31, 2022 | -19.70 Mn |
| Sep 30, 2022 | -27.88 Mn |
| Jun 30, 2022 | -27.37 Mn |
| Mar 31, 2022 | -22.11 Mn |
| Dec 31, 2021 | -21.86 Mn |
| Sep 30, 2021 | -22.57 Mn |